Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer
Mathias Worni(University of Bern), Dieter Koeberle(Kantonsspital St. Gallen), Thomas Cerny(University of Bern), Rebekah R. White(University of St.Gallen), Beat Gloor(University of Bern), Anthony W. Castleberry(Duke University Hospital), Ricardo Pietrobon(Duke Medical Center), Ulrich Güller(University Hospital of Bern)
Cited by 66
Related Papers
Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group
|Journal of Clinical Oncology|2006|409
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
|Annals of Oncology|2019|244
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
|British Journal of Cancer|1996|220
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ
|JNCI Journal of the National Cancer Institute|2015|206
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
|Journal of Clinical Oncology|2011|190